Search results

1. ESMO 2024 – Keytruda/Lenvima leap... up to a point

   ESMO 2024 – Keytruda/Lenvima leap... up to a point …

   
    

   Jacob Plieth
    
   - 09/15/2024 - 15:51

2. ESMO 2024 – Opdualag comes under fire

   ESMO 2024 – Opdualag comes under fire …

   
    

   Jacob Plieth
    
   - 09/15/2024 - 08:35

3. ESMO 2024 – Astra’s B7-H4 effort underwhelms

   ESMO 2024 – Astra’s B7-H4 effort underwhelms … inhibitor 8 Ph1/2 in solid tumours ESMO 2024: ORR 20% (9/44 PRs) in ≥1.6mg/kg; incl 25% (3/12 …

   
    

   Madeleine Armstrong
    
   - 09/15/2024 - 08:35

4. ESMO 2024 – iTeos TIGIT meets its efficacy criteria

   ESMO 2024 – iTeos TIGIT meets its efficacy criteria …

   
    

   Jacob Plieth
    
   - 09/15/2024 - 08:34

5. ESMO 2024 – Nuvalent looks beyond its late-line Alkove

   ESMO 2024 – Nuvalent looks beyond its late-line Alkove … ALK+ solid tumours   Triple meeting 2023 ESMO 2024 presentation Cutoff date 8 Aug 2023 … treated ROS1+ NSCLC   Triple Meeting 2022 ESMO 2024 presentation Cutoff date 13 Sep 2022 …

   
    

   Madeleine Armstrong
    
   - 09/15/2024 - 08:34

6. ESMO 2024 – MediLink impresses in small-cell lung cancer

   ESMO 2024 – MediLink impresses in small-cell lung cancer …

   
    

   Madeleine Armstrong
    
   - 09/14/2024 - 14:22

7. ESMO 2024 – NiKang’s case for a better Welireg

   ESMO 2024 – NiKang’s case for a better Welireg …

   
    

   Jacob Plieth
    
   - 09/14/2024 - 14:22

8. ESMO 2024 – degraders disappoint again

   ESMO 2024 – degraders disappoint again …

   
    

   Madeleine Armstrong
    
   - 09/14/2024 - 07:37

9. ESMO 2024 – no hiding Truqap’s triple-negative flop

   ESMO 2024 – no hiding Truqap’s triple-negative flop …

   
    

   Jacob Plieth
    
   - 09/14/2024 - 07:37

10. ESMO 2024 – Bristol heads for phase 3 in small-cell

    ESMO 2024 – Bristol heads for phase 3 in small-cell …

    
     

    Jacob Plieth
     
    - 09/16/2024 - 15:20